Sinus Node Dysfunction

Definition

Sinus node dysfunction (SND), historically called sick sinus syndrome, encompasses a spectrum of abnormalities in sinoatrial impulse formation and propagation: sinus bradycardia (<50 bpm), ectopic atrial bradycardia, sinoatrial exit block, sinus pause (>3 s), sinus node arrest, and tachy-brady syndrome. Chronotropic incompetence (failure to reach 80% of expected heart rate reserve with exertion) is also a manifestation. Diagnosis requires both bradycardia and symptoms; the presence of sinus bradycardia or a pause >3 s alone is insufficient.

Key Concepts

Epidemiology

• Most common in patients in their 70s–80s; incidence mirrors pacemaker implantation for AV nodal disease (both age-dependent)
• Frequent comorbidities: ischemic heart disease, HF, valvular disease, cerebrovascular disease, AF (sources/bradycardia-acc-aha-hrs-2018, rating: very high)
• Asymptomatic sinus bradycardia is NOT associated with adverse outcomes
• Symptomatic SND: high risk of syncope, AF, and HF; chronotropic incompetence associated with increased CV death and overall mortality (sources/bradycardia-acc-aha-hrs-2018, rating: very high)

Pathophysiology

• Age-dependent progressive degenerative fibrosis of the sinoatrial nodal tissue and surrounding atrial myocardium → abnormal impulse formation and propagation (sources/bradycardia-acc-aha-hrs-2018, rating: very high)
• Same fibrotic milieu responsible for atrial arrhythmias → tachy-brady syndrome (alternating bradycardia and AF/atrial flutter/atrial tachycardia)
• Sinus node fibrosis is associated with fibrosis in the AV node → SND patients can develop AV block over time (3–35% risk at 5 years after atrial PPM implantation)
• Collagen content increases with age → slower heart rate and longer sinoatrial conduction times (SACT)
• Extrinsic/secondary SND: acute MI, electrolyte abnormalities, hypothyroidism, medications (beta-blockers, calcium channel blockers, digoxin, antiarrhythmics), Lyme carditis, vagal tone

Clinical Presentation

• Symptoms range from mild fatigue to frank syncope; severity correlates with heart rate or pause duration
• Syncope present in 50% of patients who received PPM for SND in one RCT (sources/bradycardia-acc-aha-hrs-2018, rating: very high)
• Other symptoms: dyspnea on exertion (chronotropic incompetence), lightheadedness, chronic fatigue
• Symptom–bradycardia temporal correlation is the gold standard of diagnosis
• Tachy-brady syndrome: most disabling feature is recurrent syncope/presyncope from asystolic pause after termination of paroxysmal AF

Definitions

Distinguishing SND from Atrial Standstill

• The line is excitability, not the surface ECG. In SND the atrial myocardium is diseased but still excitable and still captures with pacing; in atrial standstill the atrium is electrically silent and capture fails at maximal output (≥10 mA, 2 ms). An absent P wave in either condition is unhelpful on its own. (sources/atrial-standstill-hrs-2026, rating: medium)
• SND is a pacing problem; atrial standstill is a pacing and anticoagulation problem. Atrial standstill carries a 22–54% thromboembolic burden that CHA₂DS₂-VASc does not predict, and anticoagulation is recommended at diagnosis regardless of score — an option that does not exist in ordinary SND. (sources/atrial-standstill-hrs-2026)
• Genetics should be considered when SND is young or familial. SCN5A is the most common gene in familial sick sinus syndrome, and the same loss-of-function substrate can progress to atrial standstill. EMD and NPPA are additional standstill genes.
• Feature overlap is real: both conditions arise on a fibrotic atrial substrate, and atrial electrical disease of either kind independently raises ischaemic stroke risk (isolated SND subdistribution HR 2.28 in UK Biobank). See concepts/Atrial-Standstill.

Evaluation

• Comprehensive history and physical examination: symptom timing, triggers, medications, family history
• 12-lead ECG: Class I
• Ambulatory ECG: duration selected based on symptom frequency (24–48h Holter → extended external monitor → ICM)
• Sleep apnea evaluation: treating OSA reduces frequency of nocturnal bradycardia; nocturnal bradycardia is NOT in itself an indication for PPM
• LBBB on ECG → echocardiography to exclude structural heart disease
• ICM (implantable cardiac monitor): for infrequent/unexplained syncope undiagnosed by non-invasive means (Class IIa)
• EPS: limited role in SND; can measure sinus node recovery time (SNRT) and SACT; normal values do not exclude SND

Acute Management

• Evaluate and treat reversible causes (Class I, C-EO): medications, electrolytes, MI, thyroid, infection
• Atropine (Class IIa, B-NR): for symptomatic/hemodynamically significant bradycardia; NOT effective after cardiac transplantation
• Beta-agonists (dopamine, isoproterenol, epinephrine): for refractory bradycardia unresponsive to atropine (Class IIa)
• Theophylline/aminophylline (Class IIb): for refractory bradycardia unresponsive to atropine
• Temporary pacing (Class I): transcutaneous → transvenous for hemodynamically significant bradycardia unresponsive to medical therapy

Pacing — the Short Version

Full detail, graded recommendations and device selection: concepts/Permanent-Pacing-Indications.

• The primary benefit is quality of life, not survival — no trial has shown that pacing in SND reduces mortality.
• No minimum heart rate and no minimum pause duration defines an indication; the temporal correlation is the whole of it, and it confers the highest likelihood of responding to pacing. (sources/bradycardia-acc-aha-hrs-2018, rating: very high)
• Atrial-based pacing reduces new-onset AF but nothing else. PASE, MOST, CTOPP and UKPACE showed fewer AF episodes than VVI with no difference in mortality, stroke or heart-failure hospitalisation; VVI causes pacemaker syndrome through uncoupled AV contraction, valvular regurgitation and symptomatic hypotension.
• AAI is not the default even with intact AV conduction, because 3–35% of atrially paced patients develop AV block within five years — so DDD is preferred unless that risk is very low.

Contradictions / Open Questions

• Pathophysiologic link between SND and AF (tachy-brady syndrome) remains incompletely understood — is AF a cause or consequence of SND or a shared fibrotic substrate? Active area of investigation (sources/bradycardia-acc-aha-hrs-2018, rating: very high)
• Rate-responsive pacing in SND: one RCT showed no benefit vs fixed-rate DDD pacing; confounded by high RV pacing percentage (>90%), which may have offset any rate-responsive benefit
• Ablation of AF (atrial tachyarrhythmia) in tachy-brady syndrome may obviate need for PPM — evidence from non-randomized observational data only
• Optimal monitoring duration and method for symptom-rhythm correlation remains individualized; no standardized protocol proven superior

Connections

• Related to concepts/Atrioventricular-Block — same fibrotic process; SND patients at risk for developing AV block
• Related to concepts/Permanent-Pacing-Indications — SND pacing indications
• Related to concepts/Conduction-System-Pacing — physiologic pacing considerations
• Related to entities/Atrial-Fibrillation — tachy-brady syndrome; AF treatment may prevent need for PPM
• Related to concepts/ECG-Conduction-Disturbances — ECG manifestations of SND
• Related to concepts/Atrial-Standstill — the parenchymal alternative to nodal disease; distinguished by failed atrial capture
• Related to entities/SCN5A — commonest gene in familial sick sinus syndrome

Sources

• sources/bradycardia-acc-aha-hrs-2018
• sources/atrial-standstill-hrs-2026